BHVN Earnings Date: Mar 8, 2027 (Estimated) — Biohaven Ltd.
NYSE
Updated
When is BHVN's next earnings date?
Biohaven Ltd. (BHVN) is expected to report Q4 2026 earnings on Monday, March 8, 2027 at 4:02 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.54.
How did BHVN do in its last earnings report?
In its most recent report on Oct 29, 2026, Biohaven Ltd. posted EPS of -$0.86 versus the -$0.78 estimate, a miss of 9.8%.
How much does BHVN stock move after earnings?
BHVN beat EPS estimates in 3 of its last 8 reported quarters. Over the last 7 reports the stock moved an average of 7.0% (up or down) in the day after earnings.
About Biohaven Ltd.
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
🤖 AI Earnings Analysis
FDA acceptance of Biohaven’s Vyglxia resubmission, with a 1Q27 decision goal, is a meaningful regulatory catalyst; however, the biotech’s $0.86 quarterly loss missed estimates by $0.08, keeping execution risk high.
AI-generated summary — powered by BigEarnings.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-10-29 | -0.78 | -0.86 | -9.79% | — | ❌ Miss | — | — | — | |
| 2026-08-10 | Q2 2026 | -0.76 | -0.78 | -21.88% | $0 | ❌ Miss | -0.34% | -0.55% | +3.16% |
| 2026-05-04 | Q1 2026 | -0.78 | -0.69 | +11.54% | $0 | ✅ Beat | -4.24% | -10.45% | +6.61% |
| 2026-03-02 | Q4 2025 | -1.06 | -1.21 | -14.15% | $0 | ❌ Miss | -9.65% | -13.55% | -28.37% |
| 2025-11-10 | Q3 2025 | -1.73 | -1.47 | +15.03% | $0 | ✅ Beat | -5.69% | +0.48% | +26.88% |
| 2025-08-11 | Q2 2025 | -1.72 | -1.63 | +5.23% | $0 | ✅ Beat | -9.02% | +6.58% | -1.76% |
| 2025-03-03 | Q4 2024 | -1.56 | -1.71 | -9.62% | $0 | ❌ Miss | -13.77% | -19.69% | -35.34% |
| 2024-08-08 | Q2 2024 | -1.77 | -3.50 | -97.74% | $0 | ❌ Miss | +6.25% | +7.24% | -0.66% |
Showing last 8 quarters.